Senior Dean of Faculty, Medical Care Line Executive, Gordon Cain Chair, Prof

of

Baylor College of Medicine

Printed as of 5/9/2025

Disclosures

Personal Commercial (19)

| Company Name | Relationship Category | Compensation Level | Topic Area(s) |
|---|---|--------------------------|------------------------------------|
| Self | | | |
| Abbott Laboratories | Other - Clinical Events Committee member | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| Abiomed | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| Amgen Inc. | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| AstraZeneca Pharmaceuticals | Other - Steering Committee of Evolution HF Registry | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| Bayer Healthcare Pharmaceuticals | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| Boehringer Ingelheim Pharmaceuticals, Inc | Other - Women in Cardiology Symposium | Modest (< \$5,000) | Other |
| Cardurion | Data Safety Monitoring Board | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| Cytokinetics | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| Daiichi Sankyo | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| Johnson & Johnson | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| LivaNova USA | Data Safety Monitoring Board | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| Merck & Co., Inc. | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| Novo Nordisk Inc. | Data Safety Monitoring Board | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| Regeneron | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| Renovacor | Data Safety Monitoring Board | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| Respicardia/Zoll | Other - Steering Committee for Respicardia Registry | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| Roche | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| Sanofi-Aventis | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| Vifor Pharma | Other - Steering Committee of Care HK Study | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| | | | |

Additional Personal Commercial Disclosures for Education Activities (2)

| Company Name | Relationship Category | Compensation Level | Topic Area(s) |
|--------------------------|---------------------------|--------------------|------------------------------------|
| Self | | | |
| Amgen Inc. | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| Baxter International Inc | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |

Personal Organizational or Other Non-Commercial (2)

| Non-Commercial Enity Name | Relationship Category | Compensation Level | Topic Area(s) |
|---|-------------------------|--------------------------|------------------------------------|
| Self | | | |
| ACC/AHA Task Force for Performance Measures | Other - Member | None (\$0) | General Cardiology |
| The Journal of the American College of Cardiology | Other - Editor in Chief | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 7/19/2024

URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement in the properties of the

Confidentiality, Disclosure and Assignment Agreement | Signed on 7/19/2024

URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

Embargo | Signed on 7/19/2024

URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 2/8/2024

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.